The capability to reprogram cellular metabolism in order to most effectively support proliferating cancer cells has been emerging as a hallmark of cancer. As a result, there has been a resurgence of interest in the field of tumour metabolism. Additionally, this reappearance in interest may partly be attributed to the tremendous capability of the recent technological advancement to explore the relationship between cellular metabolism and cancer to an extent which was not possible before. The most fundamental trait of cancer cells involves their ability to sustain cell proliferation in an uncontrolled manner. Uncontrolled cell growth also require intracellular metabolic adjustment to meet the continual demand of energy and macromolecules by the proliferating cells [1]. This necessity is well known to be served by increased glucose uptake and anaerobic glycolysis by cancer cells, also known as the Warburg effect [2]. This shift in tumour metabolism is critical for supporting cancer cells as increased glycolysis allows the diversion of glycolytic intermediates into various biosynthetic pathways, including those generating nucleosides and amino acids. This, in turn, facilitates the biosynthesis of the macromolecules and organelles required for assembling new cells [3]. Moreover, the Warburg-like metabolism seems to be present in many rapidly dividing embryonic tissues, once again suggesting a role in supporting the large-scale biosynthetic programs that are required for active cell proliferation [1,4]. Biochemical and molecular studies suggest several possible mechanisms by which this metabolic alteration may evolve during cancer development. These mechanisms include mitochondrial defects and malfunction, adaptation to hypoxic tumour microenvironment, oncogenic signaling, and an abnormal expression of metabolic enzymes [5]. However, it is not known that such shift in metabolism also payback to cancer promoting proteins in a way which further facilitates their function or prevents their downregulation, thereby constituting a vicious circle in favour of cancer cells. One such potential mechanism may involve the hexosamine biosynthetic pathway (HBP) and the post-translational modification of protein by b-N-acetylglcosamine (O-GlcNAc); as changes in glucose uptake and metabolism also alter nutrient signaling pathways, including HBP [6,7]. The final product of HBP is uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) [8]. The UDPGlcNAc is a donor substrate for the post-translational modification at serine and threonine residues of a wide range of proteins including proteins known to be involved in the pathogenesis and progression of cancer (e.g. proteins enhancing glucose uptake, tumour suppressors, oncogenes, metabolic enzymes and mitochondrial proteins) [9]. For example, the constitutive activation of phosphatidylinositol 3 kinase/ protein kinase B (PI3K/Akt) pathway is known to upregulates glucose uptake in cancer cells, and various components involved in this process are known to undergo O-GlcNAc modification [9,10]...